mTOR regulates TLR-induced c-fos and Th1 responses to HBV and HCV vaccines

Virologica Sinica

Volumn 30, Issue 3, 2015, Pages 174-189

  He, Li ^a,b   Zang, Aiping ^b   Du, Min ^b   Ma, Dapeng ^b,c   Yuan, Chuanping ^b   Zhou, Chun ^b   Mu, Jing ^b   Shi, Huanjing ^b   Li, Dapeng ^b   Huang, Xulin ^b   Deng, Qiang ^b   Xiao, Jianhua ^c   Yan, Huimin ^d   Hui, Lijian ^e   Lan, Ke ^b   Xiong, Sidong ^a   Li, Xiaoxia ^f   Huang, Zhong ^b   Xiao, Hui ^b  

^a SOOCHOW UNIVERSITY   (China)

^b INSTITUTE PASTEUR OF SHANGHAI   (China)

^c UNIVERSITY OF SOUTH CHINA   (China)

^d WUHAN INSTITUTE OF VIROLOGY   (China)

^e INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^f LERNER RESEARCH INSTITUTE   (United States)

Author keywords

adjuvant; c fos; hepatitis B virus (HBV); hepatitis C virus (HCV); mTOR; Toll like receptor (TLR); vaccine

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; B7 ANTIGEN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CASEIN KINASE I; HEPATITIS B VACCINE; HEPATITIS C VACCINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P35; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 18; INTERLEUKIN 23; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; OX40 LIGAND; PHOSPHATIDYLINOSITOL 3 KINASE; POLO LIKE KINASE; PROTEIN KINASE SYK; RAPAMYCIN; THYMIC STROMAL LYMPHOPOIETIN; TOLL LIKE RECEPTOR; WORTMANNIN; PROTEIN C FOS; TARGET OF RAPAMYCIN KINASE; VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CELL FRACTIONATION; CHROMATIN IMMUNOPRECIPITATION; CYTOKINE PRODUCTION; CYTOLYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; IMMUNOASSAY; INNATE IMMUNITY; MOUSE; NONHUMAN; ONCOGENE C FOS; PERITONEUM MACROPHAGE; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; T LYMPHOCYTE; TH1 CELL; WESTERN BLOTTING; ANIMAL; CELL CULTURE; DENDRITIC CELL; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; HEPACIVIRUS; HEPATITIS B VIRUS; IMMUNOLOGY; MACROPHAGE; METABOLISM;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

ANIMALS; CELLS, CULTURED; DENDRITIC CELLS; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; HEPACIVIRUS; HEPATITIS B VIRUS; INTERLEUKIN-10; INTERLEUKIN-12; MACROPHAGES; MICE; PROTO-ONCOGENE PROTEINS C-FOS; TH1 CELLS; TOLL-LIKE RECEPTORS; TOR SERINE-THREONINE KINASES; VIRAL VACCINES;

EID: 84933522869     PISSN: 16740769     EISSN: 1995820X     Source Type: Journal    
DOI: 10.1007/s12250-015-3606-3     Document Type: Article

References (38)

1. Aksoy E, Taboubi S, Torres D, Delbauve S, Hachani A, Whitehead MA, Pearce WP, Berenjeno IM, Nock G, Filloux A, Beyaert R, Flamand V, Vanhaesebroeck B. 2012. The p110delta isoform of the kinase PI(3)K controls the subcellular compartmentalization of TLR4 signaling and protects from endotoxic shock. Nat Immunol, 13: 1045–1054.
2. Almawi WY, Melemedjian OK. 2000. Clinical and mechanistic differences between FK506 (tacrolimus) and cyclosporin A. Nephrol Dial Transplant, 15: 1916–1918.
3. Amiel E, Everts B, Freitas TC, King IL, Curtis JD, Pearce EL, Pearce EJ. 2012. Inhibition of mechanistic target of rapamycin promotes dendritic cell activation and enhances therapeutic autologous vaccination in mice. J Immunol, 189: 2151–2158.
4. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, Larsen CP, Ahmed R. 2009. mTOR regulates memory CD8 T-cell differentiation. Nature, 460: 108–112.
5. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, Houghton M, Parham P, Walker CM. 1999. Analysis of a successful immune response against hepatitis C virus. Immunity, 10: 439–449.
6. Cox AL, Mosbruger T, Lauer GM, Pardoll D, Thomas DL, Ray SC. 2005. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology, 42: 104–112.
7. Dillon S, Agrawal A, Van Dyke T, Landreth G, McCauley L, Koh A, Maliszewski C, Akira S, Pulendran B. 2004. A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells. J Immunol, 172: 4733–4743.
8. Haidinger M, Poglitsch M, Geyeregger R, Kasturi S, Zeyda M, Zlabinger GJ, Pulendran B, Horl WH, Saemann MD, Weichhart T. 2010. A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation. J Immunol, 185: 3919–3931.
9. Huang J, Manning BD. 2008. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J, 412: 179–190.
10. Iwasaki A, Medzhitov R. 2010. Regulation of adaptive immunity by the innate immune system. Science, 327: 291–295.
11. Jagannath C, Bakhru P. 2012. Rapamycin-induced enhancement of vaccine efficacy in mice. Methods Mol Biol, 821: 295–303.
12. Kaiser F, Cook D, Papoutsopoulou S, Rajsbaum R, Wu X, Yang HT, Grant S, Ricciardi-Castagnoli P, Tsichlis PN, Ley SC, O’Garra A. 2009. TPL-2 negatively regulates interferon-beta production in macrophages and myeloid dendritic cells. J Exp Med, 206: 1863–1871.
13. Kundi M. 2007. New hepatitis B vaccine formulated with an improved adjuvant system. Expert Rev Vaccines, 6: 133–140.
14. Laplante M, Sabatini DM. 2012. mTOR signaling in growth control and disease. Cell, 149: 274–293.
15. Li Q, Rao RR, Araki K, Pollizzi K, Odunsi K, Powell JD, Shrikant PA. 2011. A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity. Immunity, 34: 541–553.
16. Lyakh L, Trinchieri G, Provezza L, Carra G, Gerosa F. 2008. Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans. Immunol Rev, 226: 112–131.
17. Min L, Ji Y, Bakiri L, Qiu Z, Cen J, Chen X, Chen L, Scheuch H, Zheng H, Qin L, Zatloukal K, Hui L, Wagner EF. 2012. Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nat Cell Biol, 14: 1203–1211.
18. Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. 2001. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol, 19: 683–765.
19. Naarding MA, Falkowska E, Xiao H, Dragic T. 2011. Hepatitis C virus soluble E2 in combination with QuilA and CpG ODN induces neutralizing antibodies in mice. Vaccine, 29: 2910–2917.
20. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. 2005. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol, 6: 769–776.
21. Ohtani M, Nagai S, Kondo S, Mizuno S, Nakamura K, Tanabe M, Takeuchi T, Matsuda S, Koyasu S. 2008. Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells. Blood, 112: 635–643.
22. Pan H, O’Brien TF, Zhang P, Zhong XP. 2012. The role of tuberous sclerosis complex 1 in regulating innate immunity. J Immunol, 188: 3658–3666.
23. Pichichero ME. 2008. Improving vaccine delivery using novel adjuvant systems. Hum Vaccin, 4: 262–270.
24. Qiu Q, Wang RY, Jiao X, Jin B, Sugauchi F, Grandinetti T, Alter HJ, Shih JW. 2008. Induction of multispecific Th-1 type immune response against HCV in mice by protein immunization using CpG and Montanide ISA 720 as adjuvants. Vaccine, 26: 5527–5534.
25. Saraiva M, O’Garra A. 2010. The regulation of IL-10 production by immune cells. Nat Rev Immunol, 10: 170–181.
26. Schmitz F, Heit A, Dreher S, Eisenacher K, Mages J, Haas T, Krug A, Janssen KP, Kirschning CJ, Wagner H. 2008. Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells. Eur J Immunol, 38: 2981–2992.
27. Swadling L, Klenerman P, Barnes E. 2013. Ever closer to a prophylactic vaccine for HCV. Expert Opin Biol Ther, 13: 1109–1124.
28. Thoelen S, Van Damme P, Mathei C, Leroux-Roels G, Desombere I, Safary A, Vandepapeliere P, Slaoui M, Meheus A. 1998. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine, 16: 708–714.
29. Tong NK, Beran J, Kee SA, Miguel JL, Sanchez C, Bayas JM, Vilella A, de Juanes JR, Arrazola P, Calbo-Torrecillas F, de Novales EL, Hamtiaux V, Lievens M, Stoffel M. 2005. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int, 68: 2298–2303.
30. Torresi J, Johnson D, Wedemeyer H. 2011. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol, 54: 1273–1285.
31. Trinchieri G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol, 3: 133–146.
32. Trinchieri G, Sher A. 2007. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol, 7: 179–190.
33. Wang H, Brown J, Gu Z, Garcia CA, Liang R, Alard P, Beurel E, Jope RS, Greenway T, Martin M. 2011. Convergence of the mammalian target of rapamycin complex 1- and glycogen synthase kinase 3-beta-signaling pathways regulates the innate inflammatory response. J Immunol, 186: 5217–5226.
34. Warger T, Osterloh P, Rechtsteiner G, Fassbender M, Heib V, Schmid B, Schmitt E, Schild H, Radsak MP. 2006. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood, 108: 544–550.
35. Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, Stuhlmeier KM, Kolbe T, Stulnig TM, Horl WH, Hengstschlager M, Muller M, Saemann MD. 2008. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity, 29: 565–577.
36. Weintz G, Olsen JV, Fruhauf K, Niedzielska M, Amit I, Jantsch J, Mages J, Frech C, Dolken L, Mann M, Lang R. 2010. The phosphoproteome of toll-like receptor-activated macrophages. Mol Syst Biol, 6: 371.
37. Zhu L, Yang T, Li L, Sun L, Hou Y, Hu X, Zhang L, Tian H, Zhao Q, Peng J, Zhang H, Wang R, Yang Z, Zhang L, Zhao Y. 2014. TSC1 controls macrophage polarization to prevent inflammatory disease. Nat Commun, 5: 4696.
38. Zhu Q, Egelston C, Vivekanandhan A, Uematsu S, Akira S, Klinman DM, Belyakov IM, Berzofsky JA. 2008. Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines. Proc Natl Acad Sci U S A, 105: 16260–16265.